---
document_datetime: 2024-11-21 12:23:47
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/orgovyx-epar-procedural-steps-taken-scientific-information-after-information-archive_en.pdf
document_name: orgovyx-epar-procedural-steps-taken-scientific-information-after-information-archive_en.pdf
version: success
processing_time: 5.2488188
conversion_datetime: 2025-12-21 11:22:44.792074
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Orgovyx

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10994 /202401  | Periodic Safety Update EU Single assessment - relugolix                                                      | 19/09/2024                          | 18/11/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10994/202401. |
| IA/0025              | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 04/11/2024                          | n/a                                         |                                  |                                                                                                                                            |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0024   | Update of section 4.8 of the SmPC in order to amend the frequency of an existing adverse drug reactions (ADRs) 'Myocardial infarction' from 'rare' to 'uncommon' following PSUSA 00010994/202401 procedure and based on the current available clinical trial data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to add editorial changes. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH   | 31/10/2024   |            | SmPC and PL   | SmPC new text Uncommon Myocardial infarction For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0022   | B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/09/2024   | n/a        |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0020   | Update of sections 4.2 and 4.5 of the SmPC to add information on 'Combination with other medicines for advanced hormone-sensitive prostate cancer' based on clinical studies and literature. In addition, the MAH took the opportunity to update section 5.1 of the SmPC with 2 minor corrections. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                        | 27/06/2024   | 18/11/2024 | SmPC          | SmPC new text Potential for other medicinal products to affect the exposure to relugolix Clinical interaction studies with P-gp inhibitors (erythromycin and azithromycin) and combined P-gp and strong CYP3A4 inducers (rifampicin) have shown to affect the exposure of relugolix to a clinically relevant extent. Effect of co-administration on the exposure to relugolix and associated dosing recommendations are summarised in Table 1. This list also includes expected effect and |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             | recommendations with other potentially interacting medicinal products. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10994 /202307 | Periodic Safety Update EU Single assessment - relugolix                                                                                                                                                                                                                                                                                                                                           | 08/02/2024 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                      |
| IA/0019             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                        | 09/01/2024 | n/a        |             |                                                                                                                                                        |
| N/0018              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                  | 20/12/2023 | 18/11/2024 | PL          |                                                                                                                                                        |
| PSUSA/10994 /202301 | Periodic Safety Update EU Single assessment - relugolix                                                                                                                                                                                                                                                                                                                                           | 14/09/2023 | 20/11/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10994/202301.             |
| IB/0017             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                        | 24/10/2023 | n/a        |             |                                                                                                                                                        |
| IB/0015/G           | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.a - Change to importer, batch release | 25/08/2023 | n/a        |             |                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                          |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012 | Update of section 4.5 of the SmPC based on final results from study MVT-601-9039; this is an In vitro Interaction Study of Relugolix with human OATP2B1 Uptake Transporter. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                             | 01/06/2023 | 15/09/2023 | SmPC | SmPC new text Transporter systems: Relugolix is not an inhibitor of OATP2B1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0009 | Update of section 4.5 of the SmPC to include the result from study MVT-601-057. This is a Phase I, two-part, open-label, fixed (single)-sequence, two- treatment, two-period crossover study to assess the effects of relugolix on the pharmacokinetics of total dabigatran upon co-administration of relugolix and the P-gp substrate dabigatran etexilate in healthy adult men and women. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 25/05/2023 | 15/09/2023 | SmPC | SmPC new text Upon co-administration of a single 150 mg dose of dabigatran etexilate, a P-gp substrate, with a single 120 mg dose of relugolix, the AUC0-inf and Cmax of total dabigatran was increased by 17% and 18%, respectively, which is not considered to be clinically meaningful. Therefore, clinically meaningful effects of a 120 mg dose relugolix on other P gp substrates are not expected. Considering that the 360 mg loading dose of relugolix has not been tested, dose separation of the loading dose of relugolix from administration of other P-gp substrates is |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        | advised.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008             | Update of section 4.5 of the SmPC to include the result from study MVT-601-055; this is an open- label, fixed (single)-sequence crossover phase 1 study to assess the sufficiency of dose separation to mitigate absorption-mediated increases in exposure to relugolix resulting from inhibition of intestinal P-gp by azithromycin in healthy adult men. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 25/05/2023 | 15/09/2023 | SmPC                   | Upon co-administration of a 120 mg dose of relugolix and a single 500 mg dose of azithromycin the AUC and Cmax of relugolix were increased by 1.5- and 1.6-fold, respectively, although in the median concentration-time curves increases in relugolix exposure up to 5-fold were observed 1-3 hours after dosing. When the single dose of azithromycin was administered 6 hours after the 120 mg relugolix dose, the AUC and Cmax of relugolix were increased by 1.4- and 1.3- fold, respectively; the increase in relugolix exposure in the median concentration-time curves was maximally 1.6-fold in the window 1-3 hours after dosing. Due to limited number of subjects (n=18) and high PK variability, confidence intervals around these increases were wide (for AUC from 1.0- to 2.1-fold). |
| IAIN/0014           | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                                                                         | 21/04/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0011             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                      | 31/03/2023 | 15/09/2023 | SmPC, Labelling and PL | Product information updated to add a new pack-size of 90 (3 packs of 30) film-coated tablets for Orgovyx 120 mg film-coated tablets (EU/1/22/1642/002)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10994 /202207 | Periodic Safety Update EU Single assessment - relugolix                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/02/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0007             | Submission of the bioanalytical report for testosterone measurement in the clinical study MVT- 601-3201.                                                                                                                                                                                                                                                                                                                                                                                                 | 02/02/2023 | n/a        |                        | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|             | - Other variations not specifically covered in this Annex which involve the submission studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                     | C.I.13 elsewhere of   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------|
| IAIN/0010   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/01/2023 | n/a        |                     |                       |
| IAIN/0005   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/08/2022 | n/a        |                     |                       |
| IAIN/0003/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 17/08/2022 | 15/09/2023 | Annex II and PL     |                       |
| IA/0004     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/08/2022 | n/a        |                     |                       |
| T/0002      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/06/2022 | 08/07/2022 | SmPC, Labelling and |                       |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                           |            |     | PL   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| IAIN/0001 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority | 07/06/2022 | n/a |      |